PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Exocrine Pancreatic Cancer · Carcinoma, Squamous Cell of Head and Neck
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 350 (final count)
- Started
- Jun 25, 2018
- Main results expected
- Mar 20, 2026
- Fully finished
- Mar 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03485209 · record last updated 2026-07-22 · checked 2026-11-09 15:36 UTC